Magenta Therapeutics


Seite 1 von 1
Neuester Beitrag: 15.09.21 15:56
Eröffnet am: 02.12.18 07:07 von: BICYPAPA Anzahl Beiträge: 18
Neuester Beitrag: 15.09.21 15:56 von: 11fred11 Leser gesamt: 5.352
Forum: Börse   Leser heute: 4
Bewertet mit:
1


 

1909 Postings, 2899 Tage BICYPAPAMGTA-145

 
  
    #2
1
02.12.18 07:10
A single dose of MGTA-145 mobilized large numbers of hematopoietic stem cells in hours that engrafted robustly in primates
MGTA-145-mobilized cells blocked graft-vs.-host disease (GvHD) in preclinical models
MGTA-145 to enter the clinic in the first half of 2019

 

1 Posting, 283 Tage Erdnuss@BICYPAPA

 
  
    #5
1
09.01.21 00:53
Bin indirekt über das Heidelberg Pharma Forum bzw. deinen super Beiträgen dort auf diese Aktie aufmerksam geworden.
An der Stelle vielen Dank für deine Mühen und Einschätzungen!

Wie siehst du die aktuelle Bewertung von Magenta Therapeutics bzw. mögliche Zukunftsaussichten?

Viele Grüße
Erdnuss



 

1909 Postings, 2899 Tage BICYPAPAFür mich

 
  
    #6
2
09.01.21 09:12
Für mich einer der Favoritenwerte schlechthin. Sie kommen jetzt mit MGTA-117 in die entscheidende klinische  Phasen. Direkt dahinter 45. Sollte das mit der Umsetzung mit den ADC Wirkstoffen klappen, schlummert hier ein verborgener Schatz. Geld ist noch bis etwa Q2/3  22 da. Ein riesiges Potential mit enorm vielen Möglichkeiten. Für mich in den nächsten Jahren einer meiner Favoritenwerte neben HPHA . Mal sehen, wie sie die weitere Finanzierung im nächsten Jahr sichern können. Wahrscheinlich lizensieren sie in diesem Jahr den dritten Kandidaten von HPHA ein.
Ich kann dir nur raten mal in den Jahresberichten  und Patenten zu stöbern, um zu sehen was daraus werden könnte, wenn die Umsetzung gelingt.
Die Risiken sind biotechüblich. Finanzierung und unvorhersehbare Ereignisse in der Entwicklung. Doch die vorklinischen Versuche deuten einen riesigen großen Erfolg an. Ich hab sie dieses Jahr in mein Jahresspieldepot gepackt.
Magenta ist im Augenblick mit etwa 400 Mill. $ bewertet. Sollte es günstig auch mit den Corona Verzögerungen verlaufen sehe ich hier ein ähnliches Potential wie bei HPHA.
Man braucht nur die Geduld und dicke Nerven.
Liebe Grüße und viel Erfolg.
BICYPAPA  

1909 Postings, 2899 Tage BICYPAPAMagenta Update

 
  
    #7
1
11.01.21 16:08
https://investor.magentatx.com/news-releases/...progress-and-expected

MAGENTA THERAPEUTICS HIGHLIGHTS RECENT PROGRESS AND EXPECTED TIMING OF 2021 MILESTONES, INCLUDING FOUR ONGOING AND PLANNED CLINICAL TRIALS
January 11, 2021
Download PDF
-- MGTA-145: Three Phase 2 clinical trials ongoing or planned to evaluate MGTA-145, a biologic used in combination with plerixafor to mobilize stem cells; the first clinical trial in patients with multiple myeloma (initial data expected in mid-2021); the first clinical trial with matched donors and patients with acute myeloid leukemia (AML), acute lymphocytic lymphoma (ALL) and myelodysplastic syndromes (MDS) (data expected in the second half of 2021); and the first clinical trial in patients with sickle cell disease (trial initiation expected in the second half of 2021) –

-- MGTA-117: Completing GLP toxicology and GMP manufacturing of targeted conditioning antibody-drug conjugate, MGTA-117; plans to initiate clinical trial in acute myeloid leukemia and myelodysplastic syndromes in mid-2021 –

-- Five abstracts from across Magenta’s pipeline, including four oral presentations, will be presented at the Transplantation and Cellular Therapy (TCT) Annual Meeting, to be held virtually February 8-12, 2021 –

-- Magenta also has announced the appointment of experienced biotech executive Alison Lawton to its Board of Directors --

-- Ended 2020 with cash reserves of approximately $145 million that are expected to fund the current operating plan into 2023 --

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2021-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today highlighted progress across its stem cell mobilization and collection and targeted conditioning programs, and set expectations for 2021. These updates will be discussed during a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 7:50 a.m. PST / 10:50 a.m. EST.

“I’m exceptionally proud of the entire Magenta team who continued to adapt and execute across our portfolio, despite the disruptions that characterized 2020. This past year, we continued to drive our vision to bring immune and blood systems reset to more patients. We announced four pipeline-expanding partnerships, presented clinical and pre-clinical data across our pipeline and secured the capital that we expect can fund our operations into 2023. We continue to advance four ongoing and planned clinical trials that we believe can advance our portfolio in 2021 and, for MGTA-145 specifically, can provide proof-of-concept for stem cell mobilization across multiple diseases and the first clinical data for MGTA-117 targeted conditioning,” said Jason Gardner, D. Phil., President and Chief Executive Officer, Magenta. “I am also delighted to welcome Alison Lawton’s return to Magenta’s Board of Directors. Alison brings extensive experience and leadership in both regulatory and business arenas, essential as the Magenta portfolio advances. We look forward to building on the momentum generated in 2020 as we relentlessly focus on execution.”

Stem Cell Mobilization and Collection

MGTA-145: Three Phase 2 Clinical Trials Ongoing or Planned

Autologous Stem Cell Transplant of Multiple Myeloma Patients. Previously announced ongoing enrollment continues for the Phase 2 investigator-initiated clinical trial of MGTA-145, used in combination with plerixafor, to mobilize and collect stem cells for autologous stem cell transplantation in multiple myeloma patients at Stanford University. Magenta expects that this trial will provide data on stem cell mobilization and collection, durability of engraftment in transplanted patients and disease outcomes, including progression-free survival. Initial data from the study are expected in mid-2021.

Allogeneic Donor Stem Cell Mobilization and Collection for Stem Cell Transplant in AML, ALL and MDS Patients. Through a collaboration with the National Marrow Donor Program®/Be The Match®, Magenta plans to initiate, within the next several weeks, a Phase 2 clinical trial using MGTA-145 to mobilize and collect stem cells from allogeneic donors for transplant in patients with AML, ALL and MDS. This clinical trial will evaluate stem cell mobilization, collection, cell quality, engraftment and disease outcomes, including Graft-versus-Host Disease (GvHD), which is of particular importance in the allogeneic transplant setting. Initial data from this clinical trial are expected in the second half of 2021.

Sickle Cell Disease – Stem Cell Mobilization and Collection; Cell Characterization; Pre-Clinical Gene Modification Model. In collaboration with bluebird bio, Magenta plans to initiate a Phase 2 clinical trial in the second half of 2021 to evaluate MGTA-145, in combination with plerixafor, for the mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD). Each party will characterize the cells and Magenta plans to gene-correct the cells and transplant them into established pre-clinical disease models to evaluate engraftment. Data from this clinical trial could provide proof-of-concept for MGTA-145, in combination with plerixafor, as the preferred mobilization regimen for patients with SCD and, more broadly, across all gene therapy applications where safe, reliable and rapid mobilization of quality stem cells for gene-modification and transplant are necessary components.

About MGTA-145

Magenta is developing MGTA-145 in combination with plerixafor to harness complementary mechanisms to mobilize hematopoietic stem cells (HSCs) for collection and transplantation. This combination has the potential to be the preferred mobilization regimen for safe, rapid and reliable mobilization and collection of HSCs and could improve outcomes in autologous and allogeneic stem cell transplantation.

Targeted Conditioning

MGTA-117: Plans to Initiate Phase 1 Clinical Trial in mid-2021; Initial Safety and Pharmacokinetics (PK) data to be assessed in the fourth quarter of 2021

AML and MDS. Magenta is completing its IND-enabling GLP toxicology studies and GMP manufacturing process for MGTA-117, the first antibody-drug conjugate (ADC) candidate from the company’s research platform for targeted conditioning of patients prior to receiving a stem cell transplant for blood cancers or gene therapy drug products. Later this month, Magenta expects to complete its initial discussions with the U.S. Food and Drug Administration regarding the design of the first-in-human clinical trial. Magenta expects to file an Investigational New Drug (IND) application and, upon approval, plans to initiate a Phase 1 clinical trial in mid-2021 to assess the safety and PK in the first cohort of patients in the fourth quarter of 2021.

About MGTA-117

MGTA-117, Magenta’s most advanced conditioning program, is a CD117-targeted antibody engineered for the transplant setting and conjugated to amanitin, a payload in-licensed from Heidelberg Pharma. MGTA-117 is designed to precisely deplete only hematopoietic stem and progenitor cells to clear space in the bone marrow prior to transplant, which supports long-term engraftment and disease outcomes in patients. MGTA-117 has shown high selectivity, potent efficacy, wide safety margins and broad tolerability in non-human primate models.

Cash Guidance

With focused allocation of resources on the Company’s clinical trials and advancement of its research platform, the Company now believes its cash position will fund its operations into the first quarter of 2023.  

1909 Postings, 2899 Tage BICYPAPANeue Präsentation

 
  
    #8
1
14.01.21 17:19
Neue Präsentation mit Heidelberg Pharma ADC MGTA-117 Daten.  

1293 Postings, 2985 Tage 11fred11Magenta

 
  
    #10
1
25.02.21 09:49
steht charttechnisch an der Grenze, den seit 2 Jahren dauernden Abwärtstrend zu überwinden. Dann könnte es erstmal bis ca 16 Dollar gehen. Bei den fundamentalen Aussichten sollte da nicht Schluss sein.

Hier in Deutschland wird es ja so gut wie gar nicht gehandelt. Aber kommt dann irgendwann.  

1909 Postings, 2899 Tage BICYPAPAUnd beiden

 
  
    #11
1
25.02.21 12:02
Und beiden, Magenta und HPHA,  scheint dieses Jahr der klinische Durchbruch und erste Ergebnisse mit den ATAC Amanitinen zu gelingen.  Es wäre für beide der Durchbruch zu einem Multimilliardengeschäft. Drücken wir mal die Daumen. Eigentlich sind die beiden Werte noch gar nicht richtig entdeckt und bewertet.  

1909 Postings, 2899 Tage BICYPAPAMagenta Empfehlung

 
  
    #12
1
01.03.21 15:10

1293 Postings, 2985 Tage 11fred11und hier 2020 Report

 
  
    #13
1
03.03.21 15:39

1293 Postings, 2985 Tage 11fred11und im Chart

 
  
    #14
12.04.21 15:56
an der Nas wird gerade zum 5. x die Unterstützung berührt. Wenn sie hält, heißt es, es entwickelt sich langsam ein Trend.

 

1293 Postings, 2985 Tage 11fred11hätte

 
  
    #15
13.04.21 19:52
sein können - so ist das :)

der NBI Index für BioTech ist seit ein paar Monaten am Konsolidieren. Bio Techs ohne Nachrichten gehen diesen Trend mit. Da muss man durch, wenn man sich drauf einlässt.

 

1293 Postings, 2985 Tage 11fred11bei 117

 
  
    #16
21.07.21 17:33
muss Magenta nacharbeiten, sagt die FDA. Soll nicht schwierig sein, aber verunsichert natürlich und dauert jetzt wohl bis zum 4. Q.
https://finance.yahoo.com/news/...tics-announces-u-fda-120000339.html  

1293 Postings, 2985 Tage 11fred11jetzt ist 117

 
  
    #18
15.09.21 15:56
wieder i O
https://finance.yahoo.com/news/...ounces-ind-clearance-120000766.html

Ob es jetzt gleich wieder auf die 8.90 Dollar vor der Info geht,.......?????  

   Antwort einfügen - nach oben